cnty-101
cnty-101: developed by 1 company · 2 clinical trials tracked.
cnty-101 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could cnty-101 → IPSC affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Century Therapeutics, Inc. (IPSC) Systemic Lupus Erythematosus; R/R CD19-Positive B-Cell Malig… | Phase 1 |
Clinical Trials (2)
The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases
Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs
The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies
Primary endpoint: Maximum Tolerated Dose (MTD) as Determined by the Percentage of Participants With Dose Limiting Toxicities (DLTs) and DLTs Based on Severity
Frequently asked questions
Who is developing cnty-101?
cnty-101 is being developed by Century Therapeutics, Inc..
How many clinical trials involve cnty-101?
BioSniper tracks 2 clinical trials involving cnty-101.